Clinical Rheumatology

, Volume 37, Issue 6, pp 1511–1519 | Cite as

No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis

  • Zahra Rezaieyazdi
  • Samira Tabaei
  • Yalda Ravanshad
  • Javad Akhtari
  • Hassan Mehrad-Majd
Original Article


Several studies have estimated breast cancer risk in patients with systemic lupus erythematosus (SLE) relative to the general population. However, the results have been inconclusive. Therefore, we conducted a meta-analysis to ascertain a more comprehensive conclusion. A systematic literature search of electronic databases including PubMed, Web of Science, Embase, Cochrane Library, and Scopus was conducted to identify eligible studies using multiple search strategies. Based on the degree of heterogeneity, a random-effect model was chosen to calculate the pooled standardized incidence rate (SIR) with 95% confidence interval (CI), to estimate the strength of association between SLE and breast cancer incidence risk. A total of 18 eligible studies including 110,720 patients with SLE were enrolled in this meta-analysis. The combined results showed no significant association between SLE and breast cancer incidence (SIRs = 1.012 (95% CI, 0.797–1.284)). Subgroup analysis by study type, ethnicity, follow-up years, sample size, and SLE diagnostic criteria also showed no altered risk for breast cancer incidence (the summary risk estimate of each subgroup ranged from 0.82 to 1.40 with no statistical significance). This meta-analysis suggests no direct association between SLE and risk of breast cancer incidence.


Breast cancer Meta-analysis Systemic lupus erythematosus 


Funding information

This study was supported by Mashhad University of Medical Sciences (grant number 960911).

Compliance with ethical standards




  1. 1.
    D’Cruz DP, Khamashta MA, Hughes GR (9561) Systemic lupus erythematosus. Lancet (London, England) 369:587–596CrossRefGoogle Scholar
  2. 2.
    Maidhof W, Hilas O (2012) Lupus: an overview of the disease and management options. P & T A Peer-Teviewed J Formul Manag 37(4):240–249Google Scholar
  3. 3.
    Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12(10):605–620. CrossRefPubMedGoogle Scholar
  4. 4.
    Tsokos GC, Lo MS, Reis PC, Sullivan KE (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12(12):716–730. CrossRefPubMedGoogle Scholar
  5. 5.
    Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko H-J, Ju JH, Cho CS, Kim HY, Park SH (2010) Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 29(4):381–388. CrossRefPubMedGoogle Scholar
  6. 6.
    Kiss E, Kovacs L, Szodoray P (2010) Malignancies in systemic lupus erythematosus. Autoimmun Rev 9(4):195–199. CrossRefPubMedGoogle Scholar
  7. 7.
    Cao L, Tong H, Xu G, Liu P, Meng H, Wang J, Zhao X, Tang Y, Jin J (2015) Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One 10(4):e0122964. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE (2011) Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 104(9):1478–1481. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Björnådal L, Löfström B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31(2):66–71. CrossRefPubMedGoogle Scholar
  10. 10.
    Parikh-Patel A, White RH, Allen M, Cress R (2008) Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 19(8):887–894. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin J-F, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senécal JL, Zummer M, Pope JE, Ensworth S, el-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St. Pierre Y, Clarke AE (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dey D, Kenu E, Isenberg D (2013) Cancer complicating systemic lupus erythematosus—a dichotomy emerging from a nested case-control study. Lupus 22(9):919–927. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ramsey-Goldman R, Mattai SA, Schilling E, Chiu Y-L, Alo CJ, Howe HL, Manzi S (1998) Increased risk of malignancy in patients with systemic lupus erythematosus. J Invest Med 46(5):217–222Google Scholar
  14. 14.
    Chen Y-J, Chang Y-T, Wang C-B, Wu C-Y (2010) Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 123(12):1150. e1–1150. e6CrossRefGoogle Scholar
  15. 15.
    Dreyer L, Faurschou M, Mogensen M, Jacobsen S (2011) High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheumatol 63(10):3032–3037. CrossRefGoogle Scholar
  16. 16.
    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M (2012) NewCastle–Ottawa quality assessment scale—case control studiesGoogle Scholar
  17. 17.
    Lewis RB, Castor CW, Knisley RE, Bole GG (1976) Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 19(6):1256–1260. CrossRefPubMedGoogle Scholar
  18. 18.
    Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10(7):500–504. CrossRefPubMedGoogle Scholar
  19. 19.
    Bernatsky S, Ramsey-Goldman R, Boivin JF, Joseph L, Moore AD, Rajan R, Clarke A (2003) Do traditional Gail model risk factors account for increased breast cancer in women with lupus? J Rheumatol 30(7):1505–1507PubMedGoogle Scholar
  20. 20.
    Bernatsky S, Clarke A, Ramsey-Goldman R, Joseph L, Boivin JF, Rajan R, Moore AD, Leung MH, Allen A, Gordon C (2004) Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. Rheumatology 43(9):1178–1181. CrossRefPubMedGoogle Scholar
  21. 21.
    Bernatsky S, Clarke A, Ramsey-Goldman R, Boivin J, Joseph L, Rajan R et al (2004) Breast cancer stage at time of detection in women with systemic lupus erythematosus. Lupus 13(6):469–472. CrossRefPubMedGoogle Scholar
  22. 22.
    Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, Ensworth S, Rajan R, el-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A, Ramsey-Goldman R (2005) Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53(5):781–784. CrossRefPubMedGoogle Scholar
  23. 23.
    Chun BC, Bae SC (2005) Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul, Korea. Lupus 14(8):635–638. CrossRefPubMedGoogle Scholar
  24. 24.
    Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, el-Gabalawy H, McCarthy T, St. Pierre Y, Ramsey-Goldman R, Clarke A (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52(5):1481–1490. CrossRefPubMedGoogle Scholar
  25. 25.
    Ruiz-Irastorza G, Ugarte A, Egurbide M, Garmendia M, Pijoan J, Martinez-Berriotxoa A et al (2007) Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 66(6):815–817. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hidalgo-Conde A, de Haro Liger M, Abarca-Costalago M, Alvarez Perez M, Valdivielso-Felices P, Gonzalez-Santos P et al (2013) Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus. Reumatologia Clinica 9(6):359–364. CrossRefPubMedGoogle Scholar
  27. 27.
    Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PF, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE (2017) Breast cancer in systemic lupus. Lupus 26(3):311–315. CrossRefPubMedGoogle Scholar
  28. 28.
    Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51(4):437–439. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Sweeney D, Manzi S, Janosky J, Selvaggi K, Ferri W, Medsger Jr T et al (1995) Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 22(8):1478–1482PubMedGoogle Scholar
  30. 30.
    Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheumatol 39(6):1050–1054. CrossRefGoogle Scholar
  31. 31.
    Mellemkjér L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheumatol 40(4):761–768. CrossRefGoogle Scholar
  32. 32.
    Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 39(10):1147–1152. CrossRefPubMedGoogle Scholar
  33. 33.
    Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10(6):394–400. CrossRefPubMedGoogle Scholar
  34. 34.
    Ragnarsson O, Gröndal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12(9):687–691. CrossRefPubMedGoogle Scholar
  35. 35.
    Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G et al (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus. Ann N Y Acad Sci 1108(1):76–82. CrossRefPubMedGoogle Scholar
  36. 36.
    Khaliq W, Qayyum R, Clough J, Vaidya D, Wolff AC, Becker DM (2015) Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population. Breast Cancer Res Treat 151(2):465–474. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    KH Y, Kuo CF, Huang LH, Huang WK, See LC (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan. Medicine 95(18):e3540CrossRefGoogle Scholar
  38. 38.
    Gadalla SM, Amr S, Langenberg P, Baumgarten M, Davidson WF, Schairer C, Engels EA, Pfeiffer RM, Goedert JJ (2009) Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 100(5):817–821. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Cammarata RJ, Rodnan GP, Jensen WN (1963) Systemic rheumatic disease and malignant lymphoma. Arch Intern Med 111(3):330–337. CrossRefPubMedGoogle Scholar
  40. 40.
    Bernatsky S, Easton DF, Dunning A, Michailidou K, Ramsey-Goldman R, Gordon C, Clarke AE, Foulkes W (2012) Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues. Lupus 21(8):896–899. CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Zahra Rezaieyazdi
    • 1
  • Samira Tabaei
    • 1
  • Yalda Ravanshad
    • 2
  • Javad Akhtari
    • 3
  • Hassan Mehrad-Majd
    • 2
  1. 1.Rheumatic Diseases Research CenterMashhad University of Medical SciencesMashhadIran
  2. 2.Clinical Research UnitMashhad University of Medical SciencesMashhadIran
  3. 3.Immunogenetics Research Center, Department of Medical Nanotechnology, School of Advanced Technologies in MedicineMazandaran University of Medical SciencesSariIran

Personalised recommendations